Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07139743 · ClinicalTrials.gov registry record · Phase 1
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
A Phase 1 study of Progressive Multiple Sclerosis, sponsored by Autolus Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 7
- Study locations
NCT07139743 is a Phase 1 study of Progressive Multiple Sclerosis that is actively recruiting participants, run by Autolus Limited. The registered enrollment target is 18 participants, below the 21-participant average among 3 other Progressive Multiple Sclerosis trials with a reported enrollment target (14% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT07139743, a Phase 1 study of Progressive Multiple Sclerosis, is actively recruiting participants, sponsored by Autolus Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 7
- Study locations
Study Summary
The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of participants (single-arm). The study population comprises participants with progressive forms of MS, not responsive to highly effective therapies. Upon confirmation of study eligibility, participants will receive chemotherapy (used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion. Participants will be checked closely in the 28 days following obe-cel treatment. After this, participants will be monitored to evaluate safety and efficacy up to 24 months.
Conditions Studied
Interventions
- BIOLOGICAL Obecabtagene autoleucel (obe-cel)
Study Locations (7)
Other
- Hospital Universitario Vall d'Hebron - PPDS - Barcelona
- Hospital Universitari i Politecnic La Fe de Valencia - Valencia
- Addenbrooke's Hospital - Cambridge
- Western General Hospital Edinburgh - PPDSE Edinburgh - Edinburgh
- The National Hospital for Neurology & Neurosurgery - London
- Royal Hallamshire Hospital - Sheffield
California
- Stanford University - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-08-04 |
| Est. Completion | 2029-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07139743
The ClinicalTrials.gov registry entry for NCT07139743 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 21-participant average among 3 other Progressive Multiple Sclerosis trials with a reported enrollment target (14% lower). The listed sponsor is Autolus Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Progressive Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Obecabtagene autoleucel (obe-cel) is the first listed.
NCT07139743 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Other, California.
Frequently Asked Questions
What is clinical trial NCT07139743 about?
NCT07139743 is a clinical study titled "Obe-cel in Refractory Progressive Forms of Multiple Sclerosis". The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of participants (single-arm). The study population c...
What is the current status of trial NCT07139743?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-08-04. Estimated completion is 2029-08-15.
What conditions does trial NCT07139743 study?
This clinical trial studies the following conditions: Progressive Multiple Sclerosis.
What interventions are being tested in trial NCT07139743?
The interventions under investigation include: Obecabtagene autoleucel (obe-cel) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07139743?
This trial is sponsored by Autolus Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07139743 being conducted?
This trial has 7 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ABA-101 in Participants With Progressive Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 1
-
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 1
-
Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.